Payors Urge 1st Circ. To Revive Pfizer Neurontin MDL Claims
The MDL against Pfizer consolidated cases filed by consumers and health insurance companies around the country accusing the drug company of pushing off-label uses of Neurontin that studies showed were not effective.
The appellants said U.S. District Judge Patti Saris wrongly dismissed them from the MDL...
To view the full article, register now.